Education
About Us
Working with TipRanks
Follow Us
CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
RESEARCH TOOLSreports
Total Valuation
CANbridge Pharmaceuticals Inc. has a market cap or net worth of HK$314.38M. The enterprise value is HK$255.35M.
Market CapHK$314.38M
Enterprise ValueHK$255.35M
Share Statistics
CANbridge Pharmaceuticals Inc. has 424,838,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding424,838,320
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CANbridge Pharmaceuticals Inc.’s return on equity (ROE) is 0.93 and return on invested capital (ROIC) is 100.53%.
Return on Equity (ROE)0.93
Return on Assets (ROA)-3.79
Return on Invested Capital (ROIC)100.53%
Return on Capital Employed (ROCE)0.93
Revenue Per Employee1.27M
Profits Per Employee-6.61M
Employee Count67
Asset Turnover0.73
Inventory Turnover3.90
Valuation Ratios
The current PE Ratio of CANbridge Pharmaceuticals Inc. is -0.12. CANbridge Pharmaceuticals Inc.’s PEG ratio is 0.07.
PE Ratio-0.12
PS Ratio0.00
PB Ratio-0.27
Price to Fair Value-0.11
Price to FCF-1.20
Price to Operating Cash Flow-1.20
PEG Ratio0.07
Income Statement
In the last 12 months, CANbridge Pharmaceuticals Inc. had revenue of 85.10M and earned -442.62M in profits. Earnings per share was -1.04.
Revenue85.10M
Gross Profit54.30M
Operating Income-340.51M
Pretax Income-442.62M
Net Income-442.62M
EBITDA-328.69M
Earnings Per Share (EPS)-1.04
Cash Flow
In the last 12 months, operating cash flow was -108.30M and capital expenditures -14.00K, giving a free cash flow of -108.31M billion.
Operating Cash Flow-108.30M
Free Cash Flow-108.31M
Free Cash Flow per Share-0.25
Dividends & Yields
CANbridge Pharmaceuticals Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change100.00%
50-Day Moving Average0.25
200-Day Moving Average0.20
Relative Strength Index (RSI)83.96
Average Volume (3m)12.40M
Important Dates
CANbridge Pharmaceuticals Inc. upcoming earnings date is Aug 29, 2025, Before Open (Not Confirmed).
Last Earnings DateMar 31, 2025
Next Earnings DateAug 29, 2025
Ex-Dividend Date―
Financial Position
CANbridge Pharmaceuticals Inc. as a current ratio of 0.09, with Debt / Equity ratio of -28.62%
Current Ratio0.09
Quick Ratio0.08
Debt to Market Cap0.57
Net Debt to EBITDA-0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CANbridge Pharmaceuticals Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CANbridge Pharmaceuticals Inc. EV to EBITDA ratio is -0.54, with an EV/FCF ratio of 0.00.
EV to Sales2.10
EV to EBITDA-0.54
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
CANbridge Pharmaceuticals Inc. has HK$10.50M in cash and marketable securities with ¥135.78M in debt, giving a net cash position of HK$125.28M billion.
Cash & Marketable SecuritiesHK$10.50M
Total Debt¥135.78M
Net CashHK$125.28M
Net Cash Per ShareHK$0.29
Tangible Book Value Per Share-HK$1.28
Margins
Gross margin is 63.81%, with operating margin of -400.12%, and net profit margin of -520.10%.
Gross Margin63.81%
Operating Margin-400.12%
Pretax Margin-520.10%
Net Profit Margin-520.10%
EBITDA Margin-386.23%
EBIT Margin-400.12%
Analyst Forecast
The average price target for CANbridge Pharmaceuticals Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-18.57%
EPS Growth Forecast-14.06%